PerkinElmer Receives FDA Emergency Use Authorization for Respiratory SARS-CoV-2 Panel

RT-PCR test detects and differentiates SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus WALTHAM, Mass. –(BUSINESS WIRE)–Oct. 7, 2021– PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA)


Get every new post delivered right to your inbox.

Original Source